frontiere Posted - 4 hours ago

$MGX Metagenomi ref=$1.68 — LONG and adding — interesting to see short interest increased with that slump from $2.39 to now. Volumes are tiny, likely it’s part of a basket — maybe some “short XBI on RFK” e.g. 👍 means the short squeeze here is mechanistically a high risk. I never play the MOASS game but pointing out the math. 👍 475k shs avail to short, down from 740k a week ago (at recent price highs). These 475k =81% of total shortable float, ie total=586k shares — remember, ~63% of shs oust are held by inst & insiders. 👍+ Partnered and could be expanding collab w $IONS Ionis and prior partner $MRNA Moderna (in hindsight, 👍 good for MGX to part ways in light of politics + MRNA own slump!). Prior post on XBI MGX prospects per Marks https://stocktwits.com/frontiere/message/593494847

JaelynnBanks Posted - 1 day ago

$JAZZ $IONS LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

PennySimka Posted - 1 day ago

[ $JAZZ $IONS] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

peloswing Posted - 4 days ago

Monday: The two-day Stifel Healthcare Conference will include participation from a large number of companies in the healthcare sector, including: Johnson & Johnson $JNJ Editas Medicine $EDIT Merus N.V. $MRUS Qiagen $QGEN Ionis Pharmaceuticals $IONS And others...

Muskvoice Posted - 4 days ago

$IONS Who can give me solid argument to choose between $NTLA, $CRSP and $IONS ?

frontiere Posted - 6 days ago

$MGX Metagenomi ref=$1.85 — LONG from higher and today added a lot more — GTx / Gene editing — will do a longer thesis later but it’s a fascinating ex-partner of $MRNA Moderna and 👍current partner collab w $IONS Ionis — 👍neg EV at $276m cash / 36.7m shares=$7.4 per share as of 2024-09-30 — >4x of MCap👍 — while pipeline is 🚩very early and 🚩high burn per Qtr, think this will get bid sooner or later — also our observation is RFK Jr-type new admin is friendlier to the “one and done” type therapies.

GorkyC Posted - 1 week ago

$IONS This team needs to be changed or at least take a page out of Meta's playbook, and spend within their means. At least until they prove themselves with their first success and PROFITABLE!!!! launch

GorkyC Posted - 1 week ago

$IONS Need a change in management. Stan Crooke wasn't perfect but at least he didn't spend like drunken sailors. This company hasn't launched a single drug successfully yet, but they are spending like they know what they are doing. Prove it first then you will get the benefit of the doubt. I have owned this stock for over 10 years, and am thinking of selling while I am ahead. I wont even have a meager profit if the current management keeps driving this company into the ground. This stock hit $86+ under Crooke's governance.

Sowa5000 Posted - 1 week ago

$IONS solid company, upcoming catalysts

Grreen Posted - 1 week ago

$IONS testing 24.84 again if >22.66 holds

ntlaguy Posted - 2 weeks ago

This sh*t is hilarious. The bear case for $NTLA is that patients want $IONS to make money so they will take a monthly shot for the rest of their lives instead of a one time cure 🤣🤣🤣 https://www.fool.com/investing/2024/11/06/intellia-therapeutics-just-notched-another-win-so/

krishkk Posted - 2 weeks ago

$IONS will this go up.??

briefingcom Posted - 2 weeks ago

$IONS: Ionis Pharma beats by $0.17, beats on revs; co also announces pivotal Phase 3 trial design for ION582 in Angelman Syndrome https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241106070550IONS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

OpenOutcrier Posted - 2 weeks ago

$IONS (+5.4% pre) Ionis Pharmaceuticals (IONS) Announces Pivotal Phase 3 Trial Design for ION582 - SI https://ooc.bz/l/47101

OpenOutcrier Posted - 2 weeks ago

$IONS (+4.8% pre) Ionis Pharmaceuticals GAAP EPS of -$0.95 beats by $0.21, revenue of $134M beats by $4.07M - SA https://ooc.bz/l/47036

swingingtech Posted - 2 weeks ago

$CORT $IONS $COLL https://wallstreetwaves.com/corcept-therapeutics-stock-surges-61-in-2024-a-must-buy/

DonCorleone77 Posted - 2 weeks ago

$IONS Ionis Pharmaceuticals announces pivotal Phase 3 trial design for ION582 Ionis Pharmaceuticals announced the pivotal Phase 3 study design following successful alignment with the U.S. FDA on ION582, an investigational medicine for the treatment of people living with Angelman syndrome. AS typically presents in infancy and is characterized by profound intellectual disability, impaired verbal abilities and severe motor impairment. "Following positive results for ION582 in the Phase 2 HALOS trial, we are pleased to have alignment with the FDA on the design of our Phase 3 REVEAL trial, which will address clinical endpoints that reflect the most pressing and meaningful outcomes for people living with AS and their caregivers," said Brett Monia, Ph.D., chief executive officer of Ionis. "We will enroll a broad group of individuals living with AS in the global pivotal Phase 3 trial, planned to begin in the first half of 2025. We look forward to working with the community to advance a potential new treatment targeting the underlying cause of disease in this debilitating neurological condition that has no approved medicines."

DonCorleone77 Posted - 2 weeks ago

$IONS Ionis Pharmaceuticals reports Q3 EPS (95c), consensus ($1.16) Reports Q3 revenue $134M, consensus $130.13M. "Today, we stand on the cusp of a new era for Ionis, with our first co-commercialization launch proceeding well with WAINUA, our first planned independent launch fast approaching and continued strong progress across our rich pipeline. With an upcoming December FDA action date, we are ready to independently bring olezarsen to people with familial chylomicronemia syndrome, a serious rare disease with no approved treatments in the U.S. We are similarly well positioned for our second independent launch for donidalorsen, which we believe could become a preferred treatment choice for people with hereditary angioedema, with an FDA action date of August 21, 2025," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "In parallel, we are making great progress across the rest of our rich Phase 3 pipeline. We expect Phase 3 results supporting olezarsen's second indication in severe hypertriglyceridemia and pelacarsen in Lp(a)-driven cardiovascular disease next year, as well as Phase 3 results supporting eplontersen's second indication in ATTR cardiomyopathy in the second half of 2026. We are also advancing our next wave of potentially transformational wholly owned medicines, including ION582 for Angelman syndrome, which we expect to enter Phase 3 development in the first half of next year following our positive end of Phase 2 discussion with the FDA. Our recent achievements, together with our advancing and expanding pipeline, position Ionis to deliver on our goal to bring a steady cadence of transformational medicines to people with serious diseases."

DonCorleone77 Posted - 2 weeks ago

$CVS $VERX $IONS $SIX $DIN Some notable companies reporting before tomorrow's open, with earnings consensus estimates: -- CVS Health (CVS), consensus $1.53 -- Vertex (VERX), consensus 14c -- Ionis Pharmaceuticals (IONS), consensus ($1.16) -- Six Flags (SIX), consensus $3.39 -- Dine Brands (DIN), consensus $1.34

QuantInsider Posted - 2 weeks ago

There's been quite a stir with $IONS lately, as options volume has shot up to 2.4 times the norm. That kind of spike usually suggests some serious interest from the big players. Makes me wonder if there's news on the horizon or maybe just some smart money positioning itself for what's next. Anyone else thinking this could lead to something interesting?

ChessGM Posted - 2 weeks ago

$IONS Heads up alert! Only two days until Upcoming Earnings on Wednesday, 11/6/2024 Bullish (8.5) Ionis Pharmaceuticals (IONS) has demonstrated a robust outlook based on recent developments and financial metrics. The company is expected to outperform earnings estimates, indicating strong operational performance. Over the last three years, shareholders have realized a 30% return, though there was a notable 24% drop in share price recently that raises some concern. From a financial perspective, IONS has a price-to-earnings (P/E) ratio lower than the industry average, suggesting it may be undervalued relative to its peers. The anticipated earnings per share (EPS) growth is driven by a solid pipeline, including the promising Wainzua (eplontersen), which has received a favorable recommendation from the EU's Committee for Medicinal Products for Human Use (CHMP) for treating hereditary transthyretin-mediated amyloidosis. Additionally, the Fast Track designation from the FDA for zilganersen, targeting a rare neurological disorder, highlights IONS' strategic focus on innovative and niche markets that could drive future revenue growth. Upcoming earnings reports are anticipated to further solidify IONS' position in the market. Analysts are optimistic about the company's performance, with consensus estimates suggesting a significant earnings beat in the third quarter of 2024. Historical performance reflects a trend of exceeding expectations, which could lead to a positive market reaction. Given the current trajectory of IONS and the strategic advancements in their clinical pipeline, there is potential for a favorable impact on the stock price post-earnings announcement. The market will be closely watching the webcast scheduled for November 6th, where detailed financial results will be disclosed, potentially reinforcing investor confidence and driving stock performance higher. - Funds were net buyers of $IONS during the previous reporting quarter. - Top 5 funds with large holdings in $IONS: * BVF Partners LP $152MM. CGMRank: 76% * OrbiMed Advisors LLC $113MM. CGMRank: 55% * ARK Investment Management LLC $65MM. CGMRank: 62% * Balyasny Asset Management LLC $51MM. New position. CGMRank: 68% * Adage Capital P $38MM. CGMRank: 87% - Last 10 days performance: -1% - Last 30 days performance: -3% - Last 90 days performance: -22% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.

harmongreg Posted - 10/27/24

Dragonfly Capital - 5 Trade Ideas for Monday: AGCO, Cincinnati Financial, Ionis Pharma, Lululemon and NVIDIA $AGCO $CINF $IONS $LULU $NVDA https://dragonflycap.com/5-trade-ideas-for-monday-agco-cincinnati-financialionis-pharma-lululemon-and-nvidia/

Telefon Posted - 4 weeks ago

$ELTP Elite Pharmaceuticals is on fire! It just received approval from the Israeli Ministry of Health to sell its generic version of Adderall through Dexcel Pharma. ELTP is now international and could expand into other foreign markets. The share price has risen 80% in the last two weeks, and the company is poised for more spectacular growth. The company is also waiting for FDA approval for generic Vyvanse and many other products with a total combined potential market value of over $6 billion. The CEO has stated his intention is for the company to be bought out within a year to two years. More unexpected catalysts could result in a higher SP and a buyout much sooner than that. Buy now while this is still under $1.00! $ZNTL $TTOO $AMGN $IONS

DonCorleone77 Posted - 1 month ago

$IONS $AZN Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua Ionis Pharmaceuticals (IONS) announced that Ionis' and AstraZeneca's (AZN) Wainzua has been recommended for approval by the Committee for Medicinal Products for Human Use, or CHMP, in the European Union, or EU, for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. If approved by the European Commission, Wainzua will be the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.

insiderbuyingselling Posted - 1 month ago

$IONS new insider selling: 53 shares. http://insiderbuyingselling.com/?t=IONS

swingingtech Posted - 1 month ago

$IYH $TXG $IONS $CERT https://wallstreetwaves.com/analysts-project-10-growth-potential-for-iyh/

Xmarketsthestock Posted - 1 month ago

👀 $IONS $QNTM $TEVA $TGTX $IMUX

gelk Posted - 1 month ago

Added $IONS

DonCorleone77 Posted - 1 month ago

$IONS Ionis Pharmaceuticals to present data on donidalorsen at ACAAI Ionis Pharmaceuticals announced that it will present new three-year data from the Phase 2 open-label extension study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema. Results will be presented at the 2024 American College of Allergy, Asthma & Immunology, ACAAI, Annual Scientific Meeting in Boston, Massachusetts.

DonCorleone77 Posted - 1 month ago

$IONS Ionis announces U.S. FDA granted Fast Track Designation for zilganersen Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted zilganersen Fast Track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease. Topline data from the pivotal study of zilganersen is expected in the second half of 2025. The FDA grants investigational medicines Fast Track designation to facilitate the development and expedite the review of medicines that demonstrate the potential to treat serious conditions and fill an unmet medical need. "With no approved treatments available for people living with AxD, receiving this Fast Track designation for zilganersen reflects the seriousness of this ultra-rare disease and the significant unmet need for treatment in this patient population," said Eugene Schneider, M.D., executive vice president and chief clinical development officer at Ionis. "Zilganersen was designed to address the underlying cause of disease and help improve the functioning of people living with AxD. We look forward to a data readout next year and working closely with the FDA to potentially bring forward the first approved AxD treatment."